Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency
- 15 November 2005
- journal article
- case report
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 58 (2), 272-275
- https://doi.org/10.1007/s00280-005-0139-8
Abstract
This report here is the case of a 52-year-old male patient who suffered from extremely severe haematological toxicities (G4 neutropenia, G4 thrombocytopenia) while undergoing Xelox (Xeloda + Oxaliplatin) treatment for his multifocal hepatocarcinoma. Despite appropriate supportive treatment, his condition quickly deteriorated and led to death. It was hypothesized that dihydropyrimidine deshydrogenase (DPD) gene polymorphism could be, at least in part, responsible for this fatal outcome. To test this hypothesis, both phenotypic and genotypic studies were undertaken, and fully confirmed the DPD-deficient status of this patient. Uracil to dihydrouracil ratio in plasma was evaluated as a surrogate marker for DPD deficiency, and showed values out of the range previously recorded from a reference, non-toxic population. Interestingly, the canonical IVS14+1G>A single nucleotide polymorphism, usually associated with the most severe toxicities reported with 5-fluorouracil (5-FU), was not found in this patient, but further investigations showed instead a heterozygosity for the 1896C>T mutation located in the exon 14 of the DPYD gene. Taken together, the data strongly suggest for the first time that a toxic-death case after capecitabine-containing protocol could be, at least in part, linked with a DPD-deficiency syndrome. The case reported here warrants therefore systematic detection of patients at risk, including when oral capecitabine is scheduled.Keywords
This publication has 8 references indexed in Scilit:
- Important Role of the Dihydrouracil/Uracil Ratio in Marked Interpatient Variations of Fluoropyrimidine Pharmacokinetics and PharmacodynamicsThe Journal of Clinical Pharmacology, 2004
- Dihydropyrimidine Dehydrogenase Deficiency, a Pharmacogenetic Syndrome Associated with Potentially Life-Threatening Toxicity Following 5-Fluorouracil AdministrationClinical Colorectal Cancer, 2004
- Peripheral neuropathy associated with capecitabineAnti-Cancer Drugs, 2004
- A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activityJournal of Clinical Pharmacy & Therapeutics, 2004
- Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracilEuropean Journal of Cancer, 2004
- Thymidine phosphorylase and fluoropyrimidines efficacy: a Jekyll and Hyde story.Current Medicinal Chemistry - Anti-Cancer Agents, 2004
- A High-Throughput Denaturing High-Performance Liquid Chromatography Method for the Identification of Variant Alleles Associated with Dihydropyrimidine Dehydrogenase DeficiencyAnalytical Biochemistry, 2002
- Rapid detection of a common dihydropyrimidine dehydrogenase mutation associated with 5-fluorouracil toxicity and congenital thymine uraciluria using fluorogenic hybridization probesClinical Biochemistry, 2001